Research ExplorerPublicationsDose-escalated re-irradiation improves outcome in locally re...

Dose-escalated re-irradiation improves outcome in locally recurrent head and neck cancer - Results of a large multicenter analysis

Standard

Dose-escalated re-irradiation improves outcome in locally recurrent head and neck cancer - Results of a large multicenter analysis. / Roesch, Johannes; Oertel, Michael; Wegen, Simone; Trommer, Maike; Schleifenbaum, Julia; Hering, Dominik; Mäurer, Matthias; Knippen, Stefan; Dobiasch, Sophie; Waltenberger, Maria; von der Grün, Jens; Medenwald, Daniel; Süß, Christoph; Hoeck, Michael; Käsmann, Lukas; Fleischmann, Daniel F; Rühle, Alexander; Nicolay, Nils H; Fabian, Alexander; Löser, Anastassia; Heß, Sebastian; Tamaskovics, Bálint; Vinsensia, Maria; Hecht, Markus; Young DEGRO Group.

In: RADIOTHER ONCOL, Vol. 181, 04.2023, p. 109380.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Roesch, J, Oertel, M, Wegen, S, Trommer, M, Schleifenbaum, J, Hering, D, Mäurer, M, Knippen, S, Dobiasch, S, Waltenberger, M, von der Grün, J, Medenwald, D, Süß, C, Hoeck, M, Käsmann, L, Fleischmann, DF, Rühle, A, Nicolay, NH, Fabian, A, Löser, A, Heß, S, Tamaskovics, B, Vinsensia, M, Hecht, M & Young DEGRO Group 2023, 'Dose-escalated re-irradiation improves outcome in locally recurrent head and neck cancer - Results of a large multicenter analysis', RADIOTHER ONCOL, vol. 181, pp. 109380. https://doi.org/10.1016/j.radonc.2022.10.007

APA

Roesch, J., Oertel, M., Wegen, S., Trommer, M., Schleifenbaum, J., Hering, D., Mäurer, M., Knippen, S., Dobiasch, S., Waltenberger, M., von der Grün, J., Medenwald, D., Süß, C., Hoeck, M., Käsmann, L., Fleischmann, D. F., Rühle, A., Nicolay, N. H., Fabian, A., ... Young DEGRO Group (2023). Dose-escalated re-irradiation improves outcome in locally recurrent head and neck cancer - Results of a large multicenter analysis. RADIOTHER ONCOL, 181, 109380. https://doi.org/10.1016/j.radonc.2022.10.007

Vancouver

Roesch J, Oertel M, Wegen S, Trommer M, Schleifenbaum J, Hering D et al. Dose-escalated re-irradiation improves outcome in locally recurrent head and neck cancer - Results of a large multicenter analysis. RADIOTHER ONCOL. 2023 Apr;181:109380. https://doi.org/10.1016/j.radonc.2022.10.007

Bibtex

@article{5ed9de122c6049619bf5cba4a871847a,
title = "Dose-escalated re-irradiation improves outcome in locally recurrent head and neck cancer - Results of a large multicenter analysis",
abstract = "UNLABELLED: To determine efficacy and prognostic parameters of definitive re-irradiation of locoregionally recurrent squamous cell carcinoma of the head and neck (HNSCC).MATERIALS AND METHODS: Patients with locoregionally recurrent or second primary HNSCC undergoing re-irradiation with modern radiotherapy technique were eligible for this multicentric retrospective analysis. Main endpoints were overall survival (OS), progression-free survival (PFS) and locoregional control (LC). Univariate analyses were performed using the Kaplan Meier Method (log-rank). For multivariable analysis, Cox regression was used.RESULTS: A total of 253 patients treated between 2009 and 2020 at 16 university hospitals in Germany were included. The median follow up was 27.4 months (range 0.5-130). The median OS and PFS were 13.2 (CI: 10.7 - 15.7) months and 7.9 (CI: 6.7 - 9.1) months, respectively, corresponding to two-year OS and PFS rates of 29 % and 19 %. Rates of locoregional progression and {"}in-field-failure{"} were 62 % and 51 % after two years. Multivariable Cox regression analysis identified good ECOG performance status and high radiation dose as independent prognostic parameters for OS. Doses above 50 Gy (EQD2) achieved longer median OS of 17.8 months (vs 11.7 months, p < 0.01) and longer PFS of 9.6 months (vs 6.8 months, p < 0.01). In addition, there was a trend for worse survival in patients with tracheostomy (multivariable, p = 0.061). Concomitant systemic therapy did not significantly impact PFS or OS.CONCLUSION: Re-irradiation of locally recurrent or second primary HNSCC is efficient, especially if doses above 50 Gy (EQD2) are delivered. ECOG performance score was the strongest prognostic parameter for OS and PFS.",
author = "Johannes Roesch and Michael Oertel and Simone Wegen and Maike Trommer and Julia Schleifenbaum and Dominik Hering and Matthias M{\"a}urer and Stefan Knippen and Sophie Dobiasch and Maria Waltenberger and {von der Gr{\"u}n}, Jens and Daniel Medenwald and Christoph S{\"u}{\ss} and Michael Hoeck and Lukas K{\"a}smann and Fleischmann, {Daniel F} and Alexander R{\"u}hle and Nicolay, {Nils H} and Alexander Fabian and Anastassia L{\"o}ser and Sebastian He{\ss} and B{\'a}lint Tamaskovics and Maria Vinsensia and Markus Hecht and {Young DEGRO Group}",
note = "Copyright {\textcopyright} 2022 Elsevier B.V. All rights reserved.",
year = "2023",
month = apr,
doi = "10.1016/j.radonc.2022.10.007",
language = "English",
volume = "181",
pages = "109380",
journal = "RADIOTHER ONCOL",
issn = "0167-8140",
publisher = "Elsevier Ireland Ltd",

}

RIS

TY - JOUR

T1 - Dose-escalated re-irradiation improves outcome in locally recurrent head and neck cancer - Results of a large multicenter analysis

AU - Roesch, Johannes

AU - Oertel, Michael

AU - Wegen, Simone

AU - Trommer, Maike

AU - Schleifenbaum, Julia

AU - Hering, Dominik

AU - Mäurer, Matthias

AU - Knippen, Stefan

AU - Dobiasch, Sophie

AU - Waltenberger, Maria

AU - von der Grün, Jens

AU - Medenwald, Daniel

AU - Süß, Christoph

AU - Hoeck, Michael

AU - Käsmann, Lukas

AU - Fleischmann, Daniel F

AU - Rühle, Alexander

AU - Nicolay, Nils H

AU - Fabian, Alexander

AU - Löser, Anastassia

AU - Heß, Sebastian

AU - Tamaskovics, Bálint

AU - Vinsensia, Maria

AU - Hecht, Markus

AU - Young DEGRO Group

N1 - Copyright © 2022 Elsevier B.V. All rights reserved.

PY - 2023/4

Y1 - 2023/4

N2 - UNLABELLED: To determine efficacy and prognostic parameters of definitive re-irradiation of locoregionally recurrent squamous cell carcinoma of the head and neck (HNSCC).MATERIALS AND METHODS: Patients with locoregionally recurrent or second primary HNSCC undergoing re-irradiation with modern radiotherapy technique were eligible for this multicentric retrospective analysis. Main endpoints were overall survival (OS), progression-free survival (PFS) and locoregional control (LC). Univariate analyses were performed using the Kaplan Meier Method (log-rank). For multivariable analysis, Cox regression was used.RESULTS: A total of 253 patients treated between 2009 and 2020 at 16 university hospitals in Germany were included. The median follow up was 27.4 months (range 0.5-130). The median OS and PFS were 13.2 (CI: 10.7 - 15.7) months and 7.9 (CI: 6.7 - 9.1) months, respectively, corresponding to two-year OS and PFS rates of 29 % and 19 %. Rates of locoregional progression and "in-field-failure" were 62 % and 51 % after two years. Multivariable Cox regression analysis identified good ECOG performance status and high radiation dose as independent prognostic parameters for OS. Doses above 50 Gy (EQD2) achieved longer median OS of 17.8 months (vs 11.7 months, p < 0.01) and longer PFS of 9.6 months (vs 6.8 months, p < 0.01). In addition, there was a trend for worse survival in patients with tracheostomy (multivariable, p = 0.061). Concomitant systemic therapy did not significantly impact PFS or OS.CONCLUSION: Re-irradiation of locally recurrent or second primary HNSCC is efficient, especially if doses above 50 Gy (EQD2) are delivered. ECOG performance score was the strongest prognostic parameter for OS and PFS.

AB - UNLABELLED: To determine efficacy and prognostic parameters of definitive re-irradiation of locoregionally recurrent squamous cell carcinoma of the head and neck (HNSCC).MATERIALS AND METHODS: Patients with locoregionally recurrent or second primary HNSCC undergoing re-irradiation with modern radiotherapy technique were eligible for this multicentric retrospective analysis. Main endpoints were overall survival (OS), progression-free survival (PFS) and locoregional control (LC). Univariate analyses were performed using the Kaplan Meier Method (log-rank). For multivariable analysis, Cox regression was used.RESULTS: A total of 253 patients treated between 2009 and 2020 at 16 university hospitals in Germany were included. The median follow up was 27.4 months (range 0.5-130). The median OS and PFS were 13.2 (CI: 10.7 - 15.7) months and 7.9 (CI: 6.7 - 9.1) months, respectively, corresponding to two-year OS and PFS rates of 29 % and 19 %. Rates of locoregional progression and "in-field-failure" were 62 % and 51 % after two years. Multivariable Cox regression analysis identified good ECOG performance status and high radiation dose as independent prognostic parameters for OS. Doses above 50 Gy (EQD2) achieved longer median OS of 17.8 months (vs 11.7 months, p < 0.01) and longer PFS of 9.6 months (vs 6.8 months, p < 0.01). In addition, there was a trend for worse survival in patients with tracheostomy (multivariable, p = 0.061). Concomitant systemic therapy did not significantly impact PFS or OS.CONCLUSION: Re-irradiation of locally recurrent or second primary HNSCC is efficient, especially if doses above 50 Gy (EQD2) are delivered. ECOG performance score was the strongest prognostic parameter for OS and PFS.

U2 - 10.1016/j.radonc.2022.10.007

DO - 10.1016/j.radonc.2022.10.007

M3 - SCORING: Journal article

C2 - 36273736

VL - 181

SP - 109380

JO - RADIOTHER ONCOL

JF - RADIOTHER ONCOL

SN - 0167-8140

ER -